Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 1 of the 6 sources its claims cite were checked for support.
Abstract
BACKGROUND: Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of transplantation-eligible patients with newly diagnosed multiple myeloma is needed. METHODS: In this phase 3 trial, we randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple myeloma to receive either subcutaneous daratumumab combined with VRd induction and consolidation therapy and with lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group). The primary end point was progression-free survival. Key secondary end points were a complete response or better and minimal residual disease (MRD)-negative status. RESULTS: At a median follow-up of 47.5 months, the risk of disease progression or death in the D-VRd group was lower than the risk in the VRd group. The estimated percentage of patients with progression-free survival at 48 months was 84.3% in the D-VRd group and 67.7% in the VRd group (hazard ratio for disease progression or death, 0.42; 95% confidence interval, 0.30 to 0.59; P<0.001); the P value crossed the prespecified stopping boundary (P = 0.0126). The percentage of patients with a complete response or better was higher in the D-VRd group than in the VRd group (87.9% vs. 70.1%, P<0.001), as was the percentage of patients with MRD-negative status (75.2% vs. 47.5%, P<0.001). Death occurred in 34 patients in the D-VRd group and 44 patients in the VRd group. Grade 3 or 4 adverse events occurred in most patients in both groups; the most common were neutropenia (62.1% with D-VRd and 51.0% with VRd) and thrombocytopenia (29.1% and 17.3%, respectively). Serious adverse events occurred in 57.0% of the patients in the D-VRd group and 49.3% of those in the VRd group. CONCLUSIONS: The addition of subcutaneous daratumumab to VRd induction and consolidation therapy and to lenalidomide maintenance therapy conferred a significant benefit with respect to progression-free survival among transplantation-eligible patients with newly diagnosed multiple myeloma. (Funded by the European Myeloma Network in collaboration with Janssen Research and Development; PERSEUS ClinicalTrials.gov number, NCT03710603; EudraCT number, 2018-002992-16.).
Overview
CoChat Summary
## TL;DR
The supplementary appendix for the PERSEUS trial describes a randomized comparison of subcutaneous daratumumab plus bortezomib/lenalidomide/dexamethasone (D-VRd) versus VRd alone in transplant-eligible patients with newly diagnosed multiple myeloma. It mainly provides endpoint definitions, statistical methods, eligibility criteria, subgroup results, and safety tables, but not the full primary efficacy narrative.
## Key findings
- The trial’s primary endpoint was progression-free survival; key secondary endpoints were overall complete response or better, overall minimal residual disease (MRD)-negativity, and overall survival.
- At the interim analysis, the primary endpoint was tested at an exact two-sided significance level of 0.0126, determined by 153 progression-free survival events under an Hwang-Shih-DeCani alpha-spending function.
- In prespecified subgroup analyses, D-VRd showed higher overall complete response or better rates and MRD-negativity rates across most reported subgroups; for example, MRD-negativity was 71.1% vs 45.9% in men, 81.3% vs 49.7% in women, and 78.2% vs 46.8% in patients younger than 65 years.
- Safety tables report serious adverse events in 57.0% of D-VRd patients (200/351) versus 49.3% of VRd patients (171/347); infections were the most common serious adverse event category (35.0% vs 27.4%).
## Methods
- Randomized PERSEUS study in transplant-eligible patients with newly diagnosed multiple myeloma; eligible patients were 18 to 70 years old and had ECOG performance status 0 to 2 and specified laboratory/organ-function criteria.
- The appendix specifies an intention-to-treat framework for efficacy endpoints and a safety population of patients who received at least one dose of study treatment; sample sizes in the safety tables were 351 for D-VRd and 347 for VRd.
- Main analyses included progression-free survival with two interim analyses and a final analysis, plus hierarchical testing of key secondary endpoints to control family-wise type I error; subgroup analyses are shown for complete response or better and MRD-negativity.
## Limitations
- The appendix text itself does not report the main trial’s headline efficacy results (for example, hazard ratios or median progression-free survival), so those outcomes cannot be summarized from this text alone.
- The subgroup forest plots note that the widths of confidence intervals were not adjusted for multiplicity and cannot be used to infer treatment effects.
- Evident from the provided text: this is a supplementary appendix only, so it is incomplete as a standalone paper summary.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
1 Valid · 1 Not valid · 3 Not checked · 42 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Standard risk | 182/266 (68.4) | 234/264 (88.6) | | 3.60 (2.27–5.70) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| Non-IgG | 73/96 (76.0) | 72/78 (92.3) | | 3.78 (1.45–9.83) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| ≥65 years | 62/87 (71.3) | 77/94 (81.9) | | 1.83 (0.91–3.68) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Male | 94/205 (45.9) | 150/211 (71.1) | | 2.90 (1.94–4.35) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“| <65 years | 186/267 (69.7) | 235/261 (90.0) | | 3.94 (2.43–6.37) |”
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
24 more claims
Create a free account to see all 47 claims and every source verdict.
- Probably not a substantial claim. 10
- It may state two separate claims as one. 11
- The quote only partly states this claim. 3
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The quadruplet regimen of daratumumab, bortezomib, lenalidomide, and dexamethasone (Dara-VRd) has recently emerged as standard of care option for initial therapy in transplant eligible patients with newly diagnosed myeloma.101,111”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The role of daratumumab in patients who received it as part of frontline therapy is unclear.101,152”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [101]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Daratumumab, an anti-CD38–targeting monoclonal antibody (mAb), is a cornerstone of standard-of-care MM regimens with demonstrated survival benefit across all lines.9–14”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [9]
Experimental — accuracy not yet measured
Citations
Cites
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Self-citationKumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationLenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma
Attal, M., Lauwers-Cances, V., Hulin, C., Leleu, X., Caillot, D., Escoffre, M., Arnulf, B., Macro, M., Belhadj, K., Garderet, L., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611750 · Cited by 1,257
Self-citationde Weers, M., Tai, Y.-T., van der Veer, M. S., Bakker, J. M., Vink, T., Jacobs, D. C. H., Oomen, L. A., Peipp, M., Valerius, T., Slootstra, J. W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003032 · Cited by 1,037
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMoreau, P., Attal, M., Hulin, C., Arnulf, B., Belhadj, K., Benboubker, L., Béné, M. C., Broijl, A., Caillon, H., Caillot, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31240-1 · Cited by 967
Self-citationKrejcik, J., Casneuf, T., Nijhof, I. S., Verbist, B., Bald, J., Plesner, T., Syed, K., Liu, K., van de Donk, N. W. C. J., Weiss, B. M., et al. (2016) · Blood · doi:10.1182/blood-2015-12-687749 · Cited by 954
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationGlobal Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016
Cowan, A. J., Allen, C., Barac, A., Basaleem, H., Bensenor, I., Curado, M. P., Foreman, K., Gupta, R., Harvey, J., Hosgood, H. D., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2128 · Cited by 631
Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521
Research works printed but not linked: 1
- 7. Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Semin Oncol 2016;43:676-81.
Cited by
Items 201–300 of 589
Long term responders in frontline multiple myeloma—exception vs expectation of the modern era
Baljević, M., Sborov, D. W., & Kumar, S. K. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01100-z · Cited by 3
“Fea t u r e P E T H E M A / G E M 2012 [ 4 ] I F M - 2 009 [ 5 ] D E T E R M I N A T I O N [ 6 ] C A SS I O P E I A [ 7 ] G R I FF I N [ 8 ] G MM G - HD 7 [ 9 ] P E R SE U S [ 10 ] G MM G -”
Kastritis, E., Beksaç, M., BADELITA, S. N., Katodritou, E., Bila, J., Spanoudakis, E., Seval, G. C., Cvetković, Z., Marković, O., Toprak, S. K., et al. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.08.007 · Cited by 6
Self-citationMusto, P., & Sgherza, N. (2024) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2024.073 · Cited by 4
A phase Ib trial of isatuximab, bendamustine, and prednisone in relapsed/refractory multiple myeloma
Goldsmith, S. R., Slade, M., Fiala, M. A., Harding, M., Crees, Z. D., Schroeder, M. A., Stockerl-Goldstein, K. E., & Vij, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05975-7 · Cited by 4
Saba, L., Fu, C., Liang, H., & Chaulagain, C. P. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.10.006 · Cited by 3
Engaging a New Treatment Paradigm: Elranatamab in Relapsed/Refractory Multiple Myeloma
Saied, G., & Halford, Z. (2024) · Annals of Pharmacotherapy · doi:10.1177/10600280241281742 · Cited by 4
Advances in CD19-targeting CAR-T cell therapies for multiple myeloma
Steinhardt, M., Einsele, H., & Waldschmidt, J. M. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2443093 · Cited by 3
“Despite advancements in conventional therapies, including proteasome inhibitors, immunomodulatory drugs (IMiDs), and monoclonal antibodies, MM remains incurable for most patients [1–3].”
Self-citationMarashi, M., Farsi, K. A., Al-Hateeti, H., Alhuraiji, A., Elsabah, H., Cherif, H., Hamad, A. A., Mheidly, K., Osman, H. Y., & Mohty, M. (2025) · Clinical Hematology International · doi:10.46989/001c.128113 · Cited by 3
Liu, Z., Li, X., He, Y., et al. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-05537-1 · Cited by 3
“Bortezomib (BTZ), a proteasome suppressor, has emerged as a prominent targeted drug in combating MM [9].”
Kündgen, L. J., Akhoundova, D., Hoffmann, M., Legros, M., Shaforostova, I., Seipel, K., Bacher, U., & Pabst, T. (2025) · Cancers · doi:10.3390/cancers17091565 · Cited by 3
“As no re-randomization prior to maintenance therapy was conducted, it is not possible to draw conclusions regarding the extent to which Dara-lenalidomide as a maintenance strategy offers an advantage over lenalidomide alone, regardless of induction [29].”
Lin, Z., Dong, R., Zhang, W., Liu, R., Fu, B., & He, A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2512031 · Cited by 3
“Finally, a total of 13 articles involving 8 RCTs were included (Figure 1) [12,15,18,19,34–42].”
Patient Preferences on Clinical Decision Making in Multiple Myeloma
Mohyuddin, G. R., Chakraborty, R., Berger, K., Winborg, R., Barnes, M. S., Martínez, J. A. H., Hydren, J. R., Sborov, D. W., Godara, A., McClune, B. L., et al. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00322 · Cited by 6
Hwa, Y. L., Jevremović, D., Kumar, S. K., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.70697 · Cited by 2
Interleukin 10: Bridging the chasms in the immune landscape of multiple myeloma
Fernandes, Q., Ansari, A. W., Makni‐Maalej, K., Merhi, M., Dermime, S., Ahmad, A., & Shahab Uddin, M. S. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.08.003 · Cited by 2
Martino, M. V., Gori, M., Porto, G., Policastro, G., Pitea, M., Sgarlata, A., Delfino, I. M., Cogliandro, F., Scopelliti, A., Utano, G., et al. (2024) · Cancers · doi:10.3390/cancers16193307 · Cited by 3
“Auto-SCT was also considered in the trials of DARA-based quadruplets as induction therapy in MM [5–7] and in studies investigating other anti-CD38 MoAb-based therapies in the same setting [30–32].”
MethodAlharbi, M., Bawek, S. J., Lund, I., Glenn, S. T., Green, S. D., Hassan, H., Qian, Y., & Hillengass, J. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06218-z · Cited by 2
Mateos, M., & Puig, N. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00048 · Cited by 2
Functional Cure as a New Concept of Therapy for Multiple Myeloma
Семочкин, С. В. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-2-105-120 · Cited by 3
Rodríguez‐Otero, P., Voorhees, P. M., Boccadoro, M., Laubach, J. P., Einsele, H., Sborov, D. W., Dimopoulos, M. A., Broijl, A., Mina, R., Spencer, A. G., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.04.007 · Cited by 2
Self-citationHuang, X., Zhou, J., Qian, Y., He, J., Yang, L., Wang, Z., Wei, D., Li, M., Ma, W., & Lang, H. (2025) · Systematic Reviews · doi:10.1186/s13643-025-02804-4 · Cited by 3
Alotaibi, G., Saleh, A. S. A., Alhejazi, A., Alahmadi, M. D., Motabi, I., Alsharif, F. Z., Alamer, A., Abduljalil, O., Tailor, I. K., Marei, M. A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.005 · Cited by 3
Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure
Kort, J., Rivera, A., Senigarapu, S., & Driscoll, J. J. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1578529 · Cited by 3
“The US FDA has approved a powerful four-drug combination therapy for frontline treatment of a regimen of Dara, bortezomib, Len and Dex for MM patients (68, 125 – 127).”
Encinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 9
Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma
Cumerlato, M., Maccagno, M., Labrador, M., Luciano, B., Mereu, E., Porro, M., Bandini, C., Furlan, M., Maisano, D., D’Agostino, M., et al. (2026) · Haematologica · doi:10.3324/haematol.2025.300157 · Cited by 2
Self-citationMouhieddine, T. H., Ghobrial, I. M., & Nadeem, O. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101641 · Cited by 4
Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma
Luo, K., Zhang, Z., Yao, S., Wang, Y., Amiji, M. M., & Anderson, K. C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114048 · Cited by 4
Hellou, T., Packard, D. G., Atallah‐Yunes, S. A., Orusa, A. M., Suzuki, S., Kumar, S. K., Dispenzieri, A. A., Zanwar, S., Jevremović, D., Olteanu, H., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01349-y · Cited by 3
Bahlis, N. J., Zonder, J. A., Karlin, L., Plesner, T., París, L., Wróbel, T., Hungria, V., Besemer, B., Crusoé, E., Silkjær, T., et al. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2561117 · Cited by 3
“Daratumumab-based regimens continue to demonstrate progression-free survival (PFS) and overall survival (OS) benefits in NDMM, supporting the use of frontline daratumumab [16–19].”
Self-citationBertuglia, G., Seneca, E., Corbett, T., Croft, J., Kaczmarek, P. A., Ellis, L., Neoh, C., Renaudon‐Smith, E., Vanhinsbergh, L., Lindsay, J., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.11.003 · Cited by 2
Self-citationRizzello, I., Sacchetti, I., Barbato, S., Solli, V., Stefanoni, P., Cani, L., Quaresima, M., Belotti, A., Sgherza, N., Gentile, M., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01956-w · Cited by 4
Self-citationZhang, Y., Lei, Y., Huang, Y., Gao, Y., Liu, R., Guo, K., Zhao, C., & Lei, M. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11317-1 · Cited by 2
“Despite these, the safety profile was generally manageable, and these adverse events did not affect the overall therapeutic efficacy [ 31].”
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?
Derman, B. A. (2025) · Hematology · doi:10.1182/hematology.2025000761 · Cited by 2
Mina, R., Antonioli, E., Barilà, G., Bolli, N., Botta, C., Furlan, A., Liberatore, C., Martello, M., Móre, S. M. C., Oliva, S., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.016 · Cited by 3
Self-citationHuang, Z.-Y., Liu, X.-L., Li, T., & Luo, C.-H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1729177 · Cited by 6
“…appeared uncommon: in some large RCTs such as CANDOR, the incidence of fatal adverse events was modest and not clearly attributable to daratumumab, and in the PERSEUS trial safety data described infections including pneumonia and COVID-19 but did not report an excess in mortality (41, 42).”
InfluentialRoy, P. G., Gogia, A., Anwar, Z., Mukherjee, S., & Anwer, F. (2026) · JCO Oncology Practice · doi:10.1200/op-25-00947 · Cited by 2
Jin, Y., Cheng, X., Zhang, X., Shi, Q., Zhu, Y., Li, J., Fan, L., & Chen, L. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025018945 · Cited by 2
“19,20 However, EMD-enriched analyses remain limited, and extraosseous-predominant studies show attenuated benefits (ORR, ~58%; median PFS, 5 months).”
InfluentialWang, Y., Chen, X., Liang, Q., Wang, W., Luo, J., Luo, L., Feng, R., Wei, Y., Tian, Y., Du, X., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06808-5 · Cited by 3
“Similarly, the regimens daratumumab/bortezo - mib/lenalidomide/dexamethasone (DVRd) and daratu - mumab/bortezomib/thalidomide/dexamethasone have been recommended for transplant-eligible NDMM across mul - tiple guidelines [8 , 10 , 12 ].”
Lowy, J. A., Rogers, M. F., Avigan, Z. M., Flores, M. S., Samuel, M., Rattu, M. A., & Richter, J. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2634283 · Cited by 2
Rapid Discovery of CD38 Inhibitor via DNA-Encoded Natural Product Library Screening
Shi, X., Liang, Z., Meng, W., Yang, G., & Yan, L. (2026) · Molecules · doi:10.3390/molecules31050864 · Cited by 2
Evolving understandings for the roles of CD38 protein in autoimmunity and autoimmune disease
Ye, X., Zhang, J., Song, M., Wang, P., Arés, I., López-Torres, B., Martínez, M., Martínez‐Larrañaga, M., Maximiliano, J.-E., Anadón, A., et al. (2026) · Clinical & Experimental Immunology · doi:10.1093/cei/uxag014 · Cited by 3
Dytfeld, D., Wróbel, T., Jamroziak, K., Kubicki, T., Robak, P. J., Pula, A. E., Walter‐Croneck, A., Czyż, J., Tyczyńska, A., Druzd‐Sitek, A., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00011-6 · Cited by 6
Lee, C. H., Zhang, Y., McClure, B. J., Yong, A., Scott, H. S., & Kok, C. H. (2026) · Frontiers in Digital Health · doi:10.3389/fdgth.2026.1771531 · Cited by 3
“The rapid expansion of new therapies and combinations, including triplet and quadruplet regimens further highlights the importance of longitudinal data integration (64, 65).”
Škerget, M., Trampuž, B. V., Starman, T., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15082917 · Cited by 2
“Furthermore, key randomized trials that led to the approval of daratumumab, such as Cassiopeia, Griffin, and Perseus studies, excluded patients with an eGFR of less than 30 mL/min/1.73 m 2 [17–19].”
InfluentialPaulson, R. S., Gautam, S., Medhekar, R., Mahmud, S., Mirsalehi, A., Ensley, L., Shelley, B., Brisbin, L., Lisi, M., Khare, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1736892 · Cited by 2
“Subsequently, DVRd was approved by the FDA for the treatment of SCT-eligible and SCT-ineligible patients with NDMM based on the results of the phase 3 PERSEUS and CEPHEUS trials, respectively (10, 11, 17, 18).”
Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)
Banerjee, M., Detappe, A., & Lammers, T. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115922 · Cited by 4
Antibody-Based Therapy for Transplantation-Eligible Patients with Multiple Myeloma
Stadtmauer, E. A. (2024) · New England Journal of Medicine · doi:10.1056/nejme2314067 · Cited by 2
Nørgaard, J. N., Moore, K. L. F., Slørdahl, T. S., Vik, A., Tvedt, T. H. A., & Schjesvold, F. H. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01047-1 · Cited by 4
“However, recent results from the PERSEUS trial [9], with signi fi cantly longer PFS for Daratumumab-VRD vs VRD, will most likely be practice changing.”
MethodResultSelf-citationCohen, I., Vaxman, I., & Gertz, M. A. (2024) · Acta Haematologica · doi:10.1159/000539225 · Cited by 6
“The role of maintenance therapy with dar-atumumab in addition to lenalidomide has recently been explored in the PERSEUS study [34], in which 709 patients were randomized to either induction with bortezomib, lenalidomide, and dexamethasone (VRD) or D-VRD.”
How can we stamp out high-risk myeloma?
Banerjee, R. K., & Mikhael, J. R. (2024) · Blood · doi:10.1182/blood.2024024140 · Cited by 2
Hummel, M., Hielscher, T., Emde, M., Salwender, H. J., Beck, S., Scheid, C., Bertsch, U., Goldschmidt, H., Jauch, A. S., Moreaux, J., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00613 · Cited by 2
“Effective quadruple combinations including anti-CD38 antibodies followed by ASCT increase response rates from about one-third for single agents 54-60 to almost 100% of patients 61,62 and are the evolving standard of care.”
BackgroundKastritis, E., Katodritou, E., BADELITA, S. N., Bila, J., Seval, G. C., Cvetković, Z., Coriu, D., Spanoudakis, E., Dalampira, D., Sretenović, A., et al. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2391900 · Cited by 2
“…the paucity of patients treated with qua-druplet therapy or triplets containing anti-Cd38, which has become the new standard of care in myeloma [13,14]; nonetheless, such patients were not included in the original r2-iSS development and validation cohort [4] or external validation cohorts [5–12]…”
Self-citationLiang, D., Bai, S., Feng, D., Chen, G., Liang, Y., & Wang, H. (2024) · BMC Cancer · doi:10.1186/s12885-024-12880-9 · Cited by 2
“Furthermore, transplant eligible patients in the DVRD group of this trial achieved a CR rate of 87.9% and a MRD negative rate of 75.2%, contrasting with the CR rate of 35% and MRD negative rate of 30% for transplant recipients who received VRD treatment observed in our study [22].”
ResultInfluentialThe emerging role of melflufen and peptide-conjugates in multiple myeloma
Moukalled, N. M., Dalle, I. A., Cheikh, J. E., Ye, Y., Malarad, F., Mohty, M., & Bazarbachi, A. A. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001090 · Cited by 2
Induction prior to autologous haematopoietic cell transplantation in multiple myeloma
Mohty, M., & Malard, F. (2024) · British Journal of Haematology · doi:10.1111/bjh.19753 · Cited by 3
Amitai, I., Gurion, R., Raanani, P., Vaxman, I., Yeshurun, M., Magen, H., Gafter‐Gvili, A., & Shargian, L. (2024) · Acta Haematologica · doi:10.1159/000540232 · Cited by 4
“In the recently reported PERSEUS study [25], 709 transplant-eligible patients ages 18 – 70 were randomized to VRd +/ − subcutaneous dar-atumumab (anti-CD38 monoclonal antibody; DVRd arm) from 2019 to 2020.”
InfluentialDreyling, E., Ihorst, G., Reinhardt, H., Räder, J., Holler, M., Herget, G. W., Greil, C., Wäsch, R., & Engelhardt, M. (2024) · Annals of Hematology · doi:10.1007/s00277-024-06010-5 · Cited by 6
“These patients may also receive triplets or quadruplets, tolerate longer treatment sequences, and should be included in clinical trials [ 2, 7 – 12 ].”
InfluentialEbraheem, M. S., Gertz, M. A., & Mian, H. S. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2408646 · Cited by 2
“…eligible patients with triplets containing a Pi and iMiD is currently being challenged, with multiple Rcts showing superior efficacy of qua-druplet therapy induction with the addition of an anti-cD38 mAbs, with increased depth of response and improvement in progression-free survival (PFS) [5–7].”
Blackburn, L. M., Mansour, A. G., Zhao, Q., Cottini, F., Khan, A., Bumma, N., Devarakonda, S. S., Umyarova, E. R., Rosko, A. E., Vaughn, J. E., et al. (2024) · Hemato · doi:10.3390/hemato5040030 · Cited by 2
“…followed by ASCT (using a preparative regimen of melphalan dosed at 140 mg/m 2 ) followed by lenalidomide maintenance found no differences in either PFS or OS, although this study utilized less intensive treatments and a lower dose of melphalan than those incorporated in other trials [15].”
Infections during novel myeloma therapies
Liu, A. J., Slavin, M. A., Harrison, S. J., & Teh, B. W. (2024) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2024.2428819 · Cited by 2
“…confidence interval [ci] 1.30–1.78) [29]. the respiratory tract is the most frequent site of infection reported in trial and observational data [30–32]. viral infections in general are the most common type of infection, including reactivation of latent herpes zoster viruses and hepatitis B…”
InfluentialKlomberg, K. M., Gelderloos, M., Kooistra, H., Nijland, M., Huls, G. A., Roeloffzen, W. W. H., & Plattel, W. J. (2024) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2024.12.010 · Cited by 2
Self-citationKatodritou, E., Kastritis, E., Dalampira, D., Fotiou, D., Theodorakakou, F., Delimpasi, S., Spanoudakis, E., Ntanasis‐Stathopoulos, I., Papadopoulou, T., Sevastoudi, A., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.01.002 · Cited by 2
Self-citationAre we maintaining minimal residual disease in myeloma?
Aljama, M. A., Sidiqi, M. H., & Gertz, M. A. (2025) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2025.2455485 · Cited by 2
“For example, sustained MRD negative status for at least 12 months was 64.8% in the PeRSeUS study [68]. in patients who are MRD negative, it would be important to understand the optimal maintenance therapy and duration in patients who are MRD negative.”
InfluentialSuzuki, K., Gunji, T., Nagao, R., Kawashima, M., Uryu, H., Momoki, M., Ishii, H., Fukushima, R., Katori, M., Yokoyama, H., et al. (2025) · International Journal of Hematology · doi:10.1007/s12185-025-03941-1 · Cited by 2
Chari, A., Bal, S., Ailawadhi, S., Krishnan, A. Y., Patel, K. K., Berdeja, J. G., Garfall, A. L., Callander, N. S., Banerjee, R., Alsina, M., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.03.008 · Cited by 4
Targeting the HuR/E2F7 axis synergizes with bortezomib against multiple myeloma
Jia, M., Wu, C., Fu, Z., Xu, W., Liu, J., Wu, C., Zeng, X.-Y., Wu, Y., & Yan, H. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01529-3 · Cited by 3
“Current therapies for MM mainly include proteasome inhibitors (bortezomib, car fi lzomib, and ixazomib), immunomodulators (lenalidomide and pomalidomide), B-cell maturation antigen (BCMA)- or CD38-targeted therapies, and chimeric antigen receptor T (CAR-T) cell therapies [3 – 6].”
Manubens, A., Paiva, B., Gutierrez, N. C., Fernández, M., Calasanz, M. J., Rosiñol, L., Oriol, A., Blanchard, M. J., Carrillo, E., Benavente, C., et al. (2025) · HemaSphere · doi:10.1002/hem3.70127 · Cited by 2
“5,28,29 Therefore, it would be beneficial to standardize the concept of ER independent of transplantation.”
Self-citationUpdates to Management of Multiple Myeloma
Callander, N. S., Mangan, P. A., & Kumar, S. K. (2025) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2025.5008 · Cited by 4
Ntanasis‐Stathopoulos, I., Malandrakis, P., Filippatos, C., Maganas, S., Fotiou, D., Theodorakakou, F., Spiliopoulou, V., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.003 · Cited by 3
Self-citationGordan, L., Warner, A., Heritage, T. W., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2546284 · Cited by 2
“In recent years, trials such as the MASTER study and the PERSEUS study have assessed response-adapted treatment approaches based on MRD test results [15,16].”
Kunacheewa, C., Niwatkittipon, S., Atakulreka, S., Donsakul, N., Kungwankiattichai, S., Karoopongse, E., Jianthanakanon, J., Sonsak, N., Vittayawacharin, P., Meeudompong, U., et al. (2025) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2025.10.018 · Cited by 3
Four-Drug Therapy for Multiple Myeloma
Sampath, V. S. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2402133 · Cited by 2
Diamond, B. T., Baughn, L. B., Poorebrahim, M., Poos, A. M., Lee, H., Kaddoura, M., Wiedmeier, J. E., Durante, M. A., Otteson, G. E., Jevremović, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.628799 · Cited by 2
IFN-γ and CD38 in AML: a T-cell engagement made in heaven?
Lamble, A. J., & Rau, R. E. (2024) · Blood · doi:10.1182/blood.2023023786 · Cited by 1
Costa, L. J., & Rodríguez‐Otero, P. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02842-9 · Cited by 1
Barberio, J., Lash, T. L., Nooka, A. K., Naimi, A. I., Patzer, R. E., & Kim, C. (2024) · Acta Haematologica · doi:10.1159/000539127 · Cited by 1
“More recently, the bene fi t of quadruplet regimens has been demonstrated in frontline treatment [11, 12].”
Transplant in myeloma: individualized approaches needed depending on context, access and biology
Alfaro, H. A. V., León, A. G., Desai, N., Mehra, N., & Mohyuddin, G. R. (2024) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02428-7 · Cited by 1
“With a triplet backbone of bortezomib, lenalidomide, dexamethasone (VRd), excellent outcomes have been observed [2], and the recent addition of anti-CD38 monoclonal antibodies to up-front therapy is prolonging this fi rst remission further [3].”
Tanguay, M., Roy, J., Su, J., Gul, E., Reece, D. E., Venner, C. P., White, D. J., Chu, M. P., Jimenez‐Zepada, V. H., Song, K., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70332 · Cited by 1
It’s in your (peripheral) blood
Mina, R., & D’Agostino, M. (2024) · Blood · doi:10.1182/blood.2024026783 · Cited by 1
Self-citationPasvolsky, O., Marcoux, C., Wang, Z., Milton, D. R., Pal, B., Tanner, M. R., Bashir, Q., Srour, S. A., Saini, N. Y., Lin, P. Y., et al. (2024) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2024.12.023 · Cited by 2
Siegfried, C., Amarapala, M., Leleu, X. P., & Fusfeld, L. (2025) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s498848 · Cited by 5
Self-citationAQUILA: Dousing the Embers of Smoldering Multiple Myeloma With Daratumumab Monotherapy
Lipof, J. J., Pan, D., Kumar, A. D., et al. (2025) · The Hematologist · doi:10.1182/hem.v22.2.202523 · Cited by 1
Minakata, D., Fujiwara, S., Honda, S., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02558-6 · Cited by 1
“The addition of daratumumab to induction, consolidation, and maintenance regimens confers signi fi cant bene fi ts in progression-free survival (PFS) of patients with newly diagnosed transplantation-eligible multiple myeloma (MM) [1 – 3].”
Gregory, W. M., Prior, T. J., Marriott, J. B., Sonneveld, P., Dimopoulos, M. A., Moreau, P., Usmani, S. Z., & Facon, T. T. F. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3475 · Cited by 1
“In the PERSEUS trial (27), although not designed to address the question of optimal duration, approximately two-thirds of patients who achieved durable MRD negativity after 2 years of dar-atumumab plus lenalidomide maintenance, after DVRd induction and autologous SCT, were able to stop daratumumab.”
Self-citationChannar, A., Naqvi, S. A. A., Khan, M. A., Bibi, A., Saxena, A., Tripathi, N., Iftikhar, A., Raina, A., Khakwani, K. Z. R., Riaz, I. B., et al. (2025) · Cancer Reports · doi:10.1002/cnr2.70171 · Cited by 3
“Notably, OS data remain immature for many of the included trials [10–12] with longer-term follow-up ongoing.”
Hungria, V., Moura, F. L., Costa, A., Ribeiro, E. F. O., Soares, P., Lima, J. S., Ricci, L. A., Arrais-Rodrigues, C., Nucci, F. M., Lima, M. D. M., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06365-3 · Cited by 1
“Notably, daratumumab has significantly improved clini - cal outcomes when included in frontline triplet [11] and quadruplet [13, 15, 16] regimens.”
InfluentialSelf-citationZhou, H., & Chen, W.-M. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1575914 · Cited by 1
Martins, K. A. M., Cardoso, L. J. C., Ribeiro, F. M., Pereira, A. L., Gontijo, P. H. G., Oliveira, J., Danielian, P. L. L. B., Américo, A. D., & Scheinberg, P. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.05.007 · Cited by 2
New therapeutic options and trends in the treatment of multiple myelom
Hájek, R., Muroňová, L., Mihályová, J., Horňáková, M., Popková, T., Plonková, H., & Jelínek, T. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.031 · Cited by 1
Minimal Residual Disease: Predicting and Preventing Relapse in Myeloma
Bradbury, H. (2025) · EMJ Hematology · doi:10.33590/emjhematol/ecvo9479 · Cited by 1
Clinical Benefit of Early Daratumumab Use in Multiple Myeloma is Undefined
Dijck, R. V., Erjavec, Z., & Schnog, J. B. (2025) · American Journal of Hematology · doi:10.1002/ajh.27728 · Cited by 1
Xue, H., Fang, W., & Li, R. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152373 · Cited by 1
Ali, H. M., Motiwala, Z. Y., Shatnawi, Y., Khouri, J., Anwer, F., Awada, H., Ashfaque, A., Dima, D., Williams, L. S., Ahmed, N., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.07.003 · Cited by 2
Myeloma: a sky full of MRD stars
Paiva, B., & Miguel, J. F. S. (2025) · Blood · doi:10.1182/blood.2025029160 · Cited by 1
Jang, H., Jeong, H., Sung, A., Kwon, H., Sohn, J., Kim, J., Choi, M., Huh, C., & Jung, D. (2025) · Animals · doi:10.3390/ani15162405 · Cited by 1
Systchenko, T., Nsiala, L., Bobin, A., Gardeney, H., Motard, C., Olivier, G., Borde, F., Corby, A., Roul, C., Fleck, E., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016625 · Cited by 1
Self-citationWang, X., Cui, Y., Wang, Y., & Fang, B. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06563-z · Cited by 3
“Furthermore, the PERSEUS trial demonstrated that the combination of Dara-VRd with a single auto-HSCT can deliver PFS exceeding 10 years, reinforcing the thera - peutic value of single auto-HSCT [73] and raising questions about the continued need for tandem auto-HSCT in the modern treatment era.”
InfluentialGautam, S., Morrison, L., Thompson‐Leduc, P., et al. (2025) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2025.25142 · Cited by 1
CAR-T cell therapy for multiple myeloma: An update on the current state and future potential
Pophali, P. A., Rosenblatt, J. M., & Avigan, D. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101659 · Cited by 2
Current Status of Molecularly Targeted Therapeutics in Blood Cancers
Kumala, C., Vu, L., & Fandy, T. E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110512 · Cited by 1
Wang, C., Xu, Z., Jiang, M., Chen, Y., & Lan, Y. (2025) · Cancers · doi:10.3390/cancers17213494 · Cited by 1
Metadata
- Authors
- Sonneveld, P., Dimopoulos, M. A., Boccadoro, M., Quach, H., Ho, P. J., Beksac, M., Hulin, C., Antonioli, E., Leleu, X., Mangiacavalli, S., Perrot, A., Cavo, M., Belotti, A., Broijl, A., Gay, F., Mina, R., Nijhof, I. S., van de Donk, N. W. C. J., Katodritou, E., Schjesvold, F., Sureda Balari, A., Rosiñol, L., Delforge, M., Roeloffzen, W., Silzle, T., Vangsted, A., Einsele, H., Spencer, A., Hajek, R., Jurczyszyn, A., Lonergan, S., Ahmadi, T., Liu, Y., Wang, J., Vieyra, D., van Brummelen, E. M. J., Vanquickelberghe, V., Sitthi-Amorn, A., de Boer, C. J., Carson, R., Rodriguez-Otero, P., Bladé, J., & Moreau, P.
- Affiliations
- University Medical Center Groningen (NL)
- The University of Sydney (AU)
- From the Department of Hematology, Erasmus MC Cancer Institute, Rotterdam (P.S., A. Broijl, S.L.), the Department of Hematology, Amsterdam University Medical Center and Vrije Universiteit Amsterdam, Amsterdam (I.S.N., N.W.C.J.D.), the Department of Hematology, St. Antonius Hospital, Nieuwegein (I.S.N.), University Medical Center Groningen, Groningen (W.R.), and Janssen Research and Development, Leiden (E.M.J.B., C.J.B.) — all in the Netherlands; National and Kapodistrian University of Athens, Athens (M.A.D.), and the Department of Hematology, Theagenion Cancer Hospital, Thessaloniki (E.K.) — both in Greece; the Myeloma Unit, Division of Hematology, University of Turin and Azienda Ospedaliero-Universitaria (AOU) Città della Salute e della Scienza di Torino (M. Boccadoro), the Division of Hematology 1, AOU Città della Salute e della Scienza di Torino (F.G., R.M.), and the Department of Molecular Biotechnology and Health Sciences, University of Turin (F.G., R.M.), Turin, the Department of Hematology, Careggi ...
- Oslo University Hospital (NO)
- Jagiellonian University (PL)
- ORCID
- Sonneveld, Pieter
- Dimopoulos, Meletios A.
- Boccadoro, Mario
- Quach, Hang
- Ho, P. Joy
- Hulin, Cyrille
- Antonioli, Elisabetta
- Leleu, Xavier
- Mangiacavalli, Silvia
- Perrot, Aurore
- Belotti, Angelo
- Broijl, Annemiek
- Gay, Francesca
- Mina, Roberto
- Katodritou, Eirini
- Schjesvold, Fredrik
- Rosiñol, Laura
- Delforge, Michel
- Roeloffzen, Wilfried
- Silzle, Tobias
- Vangsted, Annette
- Einsele, Hermann
- Spencer, Andrew
- Jurczyszyn, Artur
- Ahmadi, Tahamtan
- Liu, Yanfang
- Wang, Jianping
- Sitthi-Amorn, Anna
- Bladé, Joan
- Moreau, Philippe
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2024-01-25
- Volume
- 390
- Issue
- 4
- Pages
- 301-313
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4389606680
- Cited by
- 599
- References
- 23
- Citations by year
- 2026: 198 · 2025: 252 · 2024: 145
- FWCI
- 123.04
- Type
- journal article
- Language
- en
- Open access
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- European Myeloma Network in collaboration with Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, daratumumab, bortezomib, lenalidomide, dexamethasone, subcutaneous daratumumab, CD38, newly diagnosed multiple myeloma, progression-free survival, minimal residual disease, complete response, lenalidomide maintenance, neutropenia
- MeSH terms
- Bortezomib, Lenalidomide, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Humans, Membrane Glycoproteins, Multiple Myeloma, Disease Progression, ADP-ribosyl Cyclase 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.


